Podoplanin is a Useful Prognostic Marker and Indicates Better Differentiation in Lung Squamous Cell Cancer Patients? A Systematic Review and Meta-analysis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2020 May 16

PMID 32408907

Citations 3

Authors

Liya Hu

Peng Zhang

Qi Mei

Wei Sun

Lei Zhou

Tiejun Yin

Affiliations

Soon will be listed here.

Abstract

Background: The CSC (cancer stem cell) markers often indicate poor prognosis and more cell invasion or migration of cancer patients. Podoplanin was assumed as a candidate CSC marker and predict poor prognosis among squamous cancers. Whereas, the prognostic value of podoplanin among lung squamous cancer (LUSC) patients remains controversial.

Methods: A search of databases including PubMed, Embase and Web of Science was performed. Eligible articles studying the prognostic significance of podoplanin were selected. Odds ratio and HR (hazard ratio) were used to assess the relationships between podoplanin and clinical characteristics, as well as to quantify its prognostic role. The heterogeneity was estimated by I Statistic and P values from sensitivity analysis. Begg's funnel plots were used to estimate possible publication bias.

Results: 8 eligible studies containing 725 I-IV LUSC patients were included. Podoplanin expression showed no significant correlations with TNM stage, vascular invasion, lymphatic invasion, lymph node metastasis, pleural metastasis of tumor and gender of patients. However, podoplanin showed significant associations with better differentiation (pooled OR = 2.64, 95% CI 1.53-4.56, P = 0.0005, fixed effect) and better overall survival (HR = 2.14, 95% CI 1.45-3.15, P = 0.0001, fixed effect) and progression-free survival (HR = 1.73, 95% CI: 1.01-2.98, P = 0.05, fixed effect) of LUSC. Funnel plots illustrated no evidence of publication bias in our results.

Conclusions: Podoplanin could be a useful prognostic marker and indicates better differentiation for LUSC patients, and the value of PDPN expression as a marker for cancer stem cells in LUSC should be critically evaluated in future studies.

Citing Articles

Serum Podoplanin Levels as a Potential Biomarker for Diabetic Nephropathy Progression: A Cross-Sectional Study.

Huan F, Jiang X Diabetes Metab Syndr Obes. 2024; 17:4701-4710.

PMID: 39660339 PMC: 11630725. DOI: 10.2147/DMSO.S500608.

Neoplastic synovial lining cells that coexpress podoplanin and CD90 overproduce CSF-1, driving tenosynovial giant cell tumor.

Chandler A, Yakoub M, Fujiwara T, Donlin L, Purdue P, Healey J J Orthop Res. 2021; 40(8):1918-1925.

PMID: 34855235 PMC: 9160208. DOI: 10.1002/jor.25216.

Prognostic Relevance of CD4, CD8 and FOXP3 TILs in Oral Squamous Cell Carcinoma and Correlations with PD-L1 and Cancer Stem Cell Markers.

Lequerica-Fernandez P, Suarez-Canto J, Rodriguez-Santamarta T, Rodrigo J, Suarez-Sanchez F, Blanco-Lorenzo V Biomedicines. 2021; 9(6).

PMID: 34201050 PMC: 8227658. DOI: 10.3390/biomedicines9060653.

References

Ito T, Ishii G, Nagai K, Nagano T, Kojika M, Murata Y . Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies. Lung Cancer. 2008; 63(3):418-24. DOI: 10.1016/j.lungcan.2008.06.008. View

Tanaka M, Kijima H, Shimada H, Makuuchi H, Ozawa S, Inokuchi S . Expression of podoplanin and vimentin is correlated with prognosis in esophageal squamous cell carcinoma. Mol Med Rep. 2015; 12(3):4029-4036. PMC: 4526028. DOI: 10.3892/mmr.2015.3966. View

Xie L, Lin C, Zhang Q, Piao H, Bigner D, Zhang Z . Elevated expression of podoplanin and its clinicopathological, prognostic, and therapeutic values in squamous non-small cell lung cancer. Cancer Manag Res. 2018; 10:1329-1340. PMC: 5973461. DOI: 10.2147/CMAR.S163510. View

Bresson L, Faraldo M, Di-Cicco A, Quintanilla M, Glukhova M, Deugnier M . Podoplanin regulates mammary stem cell function and tumorigenesis by potentiating Wnt/β-catenin signaling. Development. 2018; 145(4). DOI: 10.1242/dev.160382. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Huong P, Nguyen L, Nguyen X, Lee S, Bach D . The Role of Platelets in the Tumor-Microenvironment and the Drug Resistance of Cancer Cells. Cancers (Basel). 2019; 11(2). PMC: 6406993. DOI: 10.3390/cancers11020240. View

Kowalczuk O, Laudanski J, Laudanski W, Niklinska W, Kozlowski M, Niklinski J . Lymphatics-associated genes are downregulated at transcription level in non-small cell lung cancer. Oncol Lett. 2018; 15(5):6752-6762. PMC: 5962861. DOI: 10.3892/ol.2018.8159. View

Hesse K, Satzger I, Schacht V, Kother B, Hillen U, Klode J . Characterisation of Prognosis and Invasion of Cutaneous Squamous Cell Carcinoma by Podoplanin and E-Cadherin Expression. Dermatology. 2016; 232(5):558-565. DOI: 10.1159/000450920. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

10.

Suzuki H, Onimaru M, Koga T, Takeshita M, Yano T, Maehara Y . High podoplanin expression in cancer cells predicts lower incidence of nodal metastasis in patients with lung squamous cell carcinoma. Pathol Res Pract. 2011; 207(2):111-5. DOI: 10.1016/j.prp.2010.11.006. View

11.

Hinterberger M, Reineke T, Storz M, Weder W, Vogt P, Moch H . D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod Pathol. 2007; 20(2):248-55. DOI: 10.1038/modpathol.3800736. View

12.

Quintanilla M, Montero-Montero L, Renart J, Martin-Villar E . Podoplanin in Inflammation and Cancer. Int J Mol Sci. 2019; 20(3). PMC: 6386838. DOI: 10.3390/ijms20030707. View

13.

Puram S, Tirosh I, Parikh A, Patel A, Yizhak K, Gillespie S . Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. Cell. 2017; 171(7):1611-1624.e24. PMC: 5878932. DOI: 10.1016/j.cell.2017.10.044. View

14.

Yang H, Cabral E, Dadras S, Cassarino D . Immunohistochemical expression of D2-40 in benign and malignant sebaceous tumors and comparison to basal and squamous cell carcinomas. Am J Dermatopathol. 2008; 30(6):549-54. DOI: 10.1097/DAD.0b013e31816d6513. View

15.

Dumoff K, Chu C, Harris E, Holtz D, Xu X, Zhang P . Low podoplanin expression in pretreatment biopsy material predicts poor prognosis in advanced-stage squamous cell carcinoma of the uterine cervix treated by primary radiation. Mod Pathol. 2006; 19(5):708-16. DOI: 10.1038/modpathol.3800580. View

16.

Astarita J, Acton S, Turley S . Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol. 2012; 3:283. PMC: 3439854. DOI: 10.3389/fimmu.2012.00283. View

17.

Astarita J, Cremasco V, Fu J, Darnell M, Peck J, Nieves-Bonilla J . The CLEC-2-podoplanin axis controls the contractility of fibroblastic reticular cells and lymph node microarchitecture. Nat Immunol. 2014; 16(1):75-84. PMC: 4270928. DOI: 10.1038/ni.3035. View

18.

Ugorski M, Dziegiel P, Suchanski J . Podoplanin - a small glycoprotein with many faces. Am J Cancer Res. 2016; 6(2):370-86. PMC: 4859667. View

19.

Atsumi N, Ishii G, Kojima M, Sanada M, Fujii S, Ochiai A . Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochem Biophys Res Commun. 2008; 373(1):36-41. DOI: 10.1016/j.bbrc.2008.05.163. View

20.

Parhar S, Kaur H, Vashist A, Verma S . Role of podoplanin in potentially malignant disorders and oral squamous cell carcinoma and its correlation with lymphangiogenesis. Indian J Cancer. 2016; 52(4):617-22. DOI: 10.4103/0019-509X.178427. View